Dr. Alka Chaubey, chief medical officer at Bionano, will host a sponsored vendor panel presentation on the integration of optical genome mapping (OGM) and next generation sequencing (NGS) for clinical research in leukemia and lymphoma
Four scientific platform presentations, one each by Dr. Ha Nguyen, MD Anderson Cancer Center, Dr. Adam Smith, University Health Network, Dr. Thuy Phung, University of South Alabama, and Dr. Nikhil Sahajpal, Augusta University, will cover the use of OGM in research on topics including hematological malignancies, angiosarcoma, and myeloid cancers
Twelve scientific poster presentations will illustrate the application of Bionano’s OGM technology in research areas including solid tumor analysis, hematological malignancies, MDS, AML, pediatric brain tumors, and
postnatal constitutional genetics
Bionano is a Diamond Sponsor at the conference, and will host customers, KOLs, and VIPs from the genomics and cytogenetics communities at an evening reception
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation at the Cancer Genomics Consortium (CGC) 2022 Annual Meeting with 18 events including a panel discussion, scientific platform presentations, facilitated roundtable, and poster presentations from Bionano and a wide variety of independent researchers from across the cancer genomics landscape.
CGC’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in clinical genomics for cancer research. CGC conference sessions will take place July 31- August 3, 2022, in St. Louis, Missouri with an option for virtual attendance. Bionano will exhibit its complete portfolio of products and services relevant to the cancer research community including OGM solutions, NxClinical™ software and laboratory services.
As part of a sponsored spotlight panel, Bionano’s chief medical officer, Alka Chaubey, will host a discussion titled “Optical Genome Mapping and its Integration with NGS for Clinical Research in Leukemia and Lymphoma,” featuring cancer genomics experts Dr. Ravindra Kolhe, from the Medical College of Georgia/Augusta University, Dr. Yassmine Akkari, from Nationwide Children’s Hospital, Dr. Rashmi Kanagal-Shamanna, from MD Anderson Cancer Center, and Dr. Brynn Levy, from Columbia University Medical Center and the New York Presbyterian Hospital. The presentation will take place Tuesday, August 2, from 4:45-5:30 PM CST in the General Session room.
Four separate scientific presentations, featuring the use of OGM in cancer research will be given. Dr. Adam Smith of University Health Network will present on international working group recommendations for the use of OGM in hematological malignancy research. Dr. Ha Nguyen of MD Anderson Cancer Center will present on homologous recombination DNA repair deficiency in hematological malignancies. Dr. Thuy Phung of University of South Alabama will present on the identification of novel structural variants (SVs) in angiosarcoma using OGM. Dr. Nikhil Sahajpal of Augusta University will present on the integration of OGM and a 523-gene panel for comprehensive genomic evaluation of myeloid cancers. Dr. Smith will also facilitate a roundtable discussion on the detection of gene rearrangements by OGM and NGS.
In addition, 12 posters featuring results from OGM applications in cytogenetics and cancer research will be presented at the conference. The full content of the posters will be made available on the Bionano Genomics website once presented at the conference. More details on the conference can be found
Scientific presentations and poster sessions from Bionano and collaborators include:
Integrating Novel Genomic Alterations for Pathologic Classification and Clinical Risk Assessment in Pediatric and Adult Leukemias
|Homologous Recombination DNA Repair Deficiency in Hematological Malignancies||Nguyen H.||July 31, 2022
Implementation of New and Emerging Technologies in Oncologic Laboratories for Improving Patient Care
|International Working Group Recommendations for the Implementation of Optical Genome Mapping in Hematologic Malignancies||Smith A.||August 1, 2022
Application of High-Depth and Novel Genomic Testing Methodologies in the Comprehensive Analyses of Vascular Anomalies and Somatic Mosaic Disorders
|Identification of Novel Genomic Structural Variations in Angiosarcoma by Optical Genome Mapping||Phung T.||August 1, 2022
Round Table Session
|Detection of Gene Rearrangements by Next Generation Sequencing (NGS) and Optical Genome Mapping||Smith A.||August 2, 2022
Expanded Horizons in Hematologic Malignancies: Clonal Behaviors and Novel Genomic Approaches
|Optical Genome Mapping and 523-Gene Sequencing Panel for Comprehensive Genomic Evaluation of Myeloid Cancers||Sahajpal N.||August 2, 2022
Diamond Vendor Showcase:
|Optical Genome Mapping and its Integration with NGS for Clinical Research in Leukemia and Lymphoma||Chaubey A.||August 2, 2022
|Optical Genome Mapping Workflow for Somatic Abnormality Detection in Multiple Solid Tumor Types||Hastie A.|
|Use of Optical Genome Mapping and Next Generation Sequencing to Construct a Comprehensive Somatic Variation Map in a Cancer Cell Line||Pang A.|
|Comparison of Optical Genome Mapping, CMA, and 523-gene NGS panel for Homologous Recombination Deficiency Calculation||Sahajpal N.|
|Optical Genome Mapping: Clinical Validation and Diagnostic Utility for Cytogenomic Analysis of Hematological Neoplasms||Sahajpal N.|
|Concordance of Integrated Analysis Approaches to Measure Genomic Instability Associated with Homologous Recombination Deficiency (HRD) Using TCGA Ovarian Cancer Dataset||Shams S.|
|Optical Genome Mapping Workflow for Identification and Analysis of Variants in Hematological Malignancies||Yu J.|
|Optical Genome Mapping Reveals Novel Structural Variants in Pediatric Brain Tumors||Bornhorst M.|
|Optical Genome Mapping for Somatic Abnormality Detection in Multiple Solid Tumor Types||Clifford B.|
|Optical Genome Mapping: Unravelling the Genomic Landscape of Solitary Fibrous Tumor||Salguero-Aranda C.|
|Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation||Levy B.|
|Optical Genome Mapping for Constitutional Postnatal SV, CNV, and Repeat Array Sizing: A Multi-site Clinical Study||Sahajpal N.|
|Optical Genome Mapping and NGS for Identification of All Classes of Variants||Yu J.|
“Bionano attended its first CGC conference six years ago, with only a few sales representatives and our scientific affairs director in attendance. During the meeting, we recognized that OGM could have a significant impact on cancer genomic research. This year’s CGC meeting, with the greatest number of presentations featuring OGM to date, illustrates the importance of it in cancer research. We are excited to see how much more of an impact OGM may make in the future,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano Genomics.
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit
Forward-Looking Statements of Bionano Genomics
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “could,” “may,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) convey uncertainty of future events or outcomes are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the ability and utility of OGM to impact cancer research, or to integrate with next generation sequencing (NGS) to provide a more comprehensive analysis of the genome for applications in cancer research. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; failure OGM to achieve useful complementarity with NGS; future study results contradicting the results reported in the presentations given and posters made available at the CGC 2022 Annual Meeting; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2021 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
+1 (858) 366-3243